Provita Profamilia
- Address
- Ul. Kostromska 66a, 97-300 Piotrkow Trybunalski, Poland
Neoplasms – Bladder Cancer Research
The research program at Provita Profamilia concentrates on non‑muscle invasive bladder cancer, advancing immunotherapy strategies within the neoplasm therapeutic area.
- Combination immunotherapy with durvalumab and BCG
- Evaluation of disease‑free survival outcomes
- Safety profiling of intravesical treatments
- Comparative analysis against standard BCG therapy
Six investigators at the Piotrkow Trybunalski site are conducting two clinical trials that test a checkpoint‑inhibitor plus BCG regimen, aiming to improve long‑term disease control for patients with early‑stage bladder cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Provita Profamilia
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Cardiovascular Safety of Cagrilintide and Semaglutide in Participants with Established Cardiovascular Disease | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 1 | Unknown | 2023-02-28 | 2023-02-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.